Skip to main content
Download PDF

Transcriptome sequencing and network pharmacology-based approach to reveal the effect and mechanism of Ji Chuan Jian against Parkinson’s disease

BMC Complementary Medicine and Therapies volume 23, Article number: 182 (2023) Cite this article

Abstract

Background

Ji Chuan Jian (JCJ), a classic Traditional Chinese Medicine (TCM) formula, has been widely applied in treating Parkinson’s disease (PD) in China, However, the interaction of bioactive compounds from JCJ with the targets involved in PD remains elusive.

Methods

Based on the transcriptome sequencing and network pharmacology approaches, the chemical compounds of JCJ and gene targets for treating PD were identified. Then, the Protein-protein interaction (PPI) and “Compound-Disease-Target” (C-D-T) network were constructed by using of Cytoscape. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were applied to these target proteins. Finally, AutoDock Vina was used for applying molecular docking.

Results

In the present study, a total number of 2669 differentially expressed genes (DEGs) were identified between PD and healthy controls using whole transcriptome RNA sequencing. Then, 260 targets of 38 bioactive compounds in JCJ were identified. Of these targets, 47 were considered PD-related targets. Based on the PPI degree, the top 10 targets were identified. In C-D-T network analysis, the most important anti-PD bioactive compounds in JCJ were determined. Molecular docking revealed that potential PD-related targets, matrix metalloproteinases-9 (MMP9) were more stably bound with naringenin, quercetin, baicalein, kaempferol and wogonin.

Conclusion

Our study preliminarily investigated the bioactive compounds, key targets, and potential molecular mechanism of JCJ against PD. It also provided a promising approach for identifying the bioactive compounds in TCM as well as a scientific basis for further elucidating the mechanism of TCM formulae in treating diseases.

Peer Review reports

Introduction

Parkinson’s disease (PD) is a multifactorial neurodegenerative movement disorder that is associated with the progressive impairment of voluntary motor control [1]. The clinical symptoms of PD mainly include motor symptoms such as bradykinesia, static tremor, postural instability, and hypokinesia [2], the non-motor symptoms such as autonomic nerve dysfunction, gastrointestinal dysfunction, bladder dysfunction, and even fatigue are also considered as important components of PD [3]. The major pathological changes of PD are the loss of dopaminergic neurons in the substantia nigra of the midbrain leading to the significant reduction of dopamine content in the striatum, and the presence of Lewy body (LB) in the substantia nigra and locus coeruleus [4, 5]. In recent years, the incidence rate of PD is increasing rapidly. It is estimated that by 2030, PD patients in China will reach 4.94 million, accounting for about 50% of patients in the world [6]. PD treatment involves pharmacologic approaches (mainly levodopa) and nonpharmacologic approaches (i.g., exercise or physical therapies) [7]. However, to date, for all patients with PD, treatment is symptomatic, no agents have been shown to have unequivocal evidence of disease-modifying effects in PD [8]. Thus, a better understanding of PD’s pathogenesis, alongside the exploration of novel medicine approaches is urgently needed.

Ji Chuan Jian (JCJ) is a classic Traditional Chinese Medicine (TCM) formula first mentioned in a famous ancient medicine treatise, “Jing Yue Quan Shu”, which was written by Zhang Jingyue, a physician in the Ming Dynasty. JCJ is composed of six herbal drugs: Angelica sinensis (Chinese name: Danggui (DG)), Achyranthes bidentata (Chinese name: Niuxi (NX)), Aurantii Fructus (Chinese name: Zhiqiao (ZQ)), Rhizoma Cimicifugae (Chinese name: Shengma (SM)), Cistanche deserticola (Chinese name: Roucongrong (RCR)), Alisma orientalis (Chinese name: Zexie (ZX)). In clinical practice, JCJ is used to improve the constipation symptoms of patients with PD, alleviate the motor symptoms and reduce the adverse reactions of anti-PD drugs in a long term [9, 10]. In experimental studies, Achyranthes bidentata polypeptide, a bioactive substance extracted from Achyranthes bidentata, showed a dopaminergic neuronal protective effect in PD models [11]. Another agent Echinacoside, the major active constituent of Cistanche deserticola, was found to exert neuroprotection in PD through IL-6/JAK2/STAT3 and NLRP3/Caspase-1/IL-1β anti-inflammatory pathway [12, 13]. Although JCJ has been used for a long time and has received significant experimental and clinical support, its active ingredients, putative target genes, and underlying mechanisms for treating PD have yet to be fully elucidated.

In the present study, we used transcriptome sequencing and a network pharmacology-based approach, as well as molecular docking technology to explore the relevant biological pathways associated with JCJ in treating PD. This is the first systematic research on the effects and mechanisms of JCJ, which will provide a theoretical basis for clinical application. A workflow chart is shown in Fig. 1.

Fig. 1
figure 1

Workflow of the study design. JCJ for the potential treatment of PD based on transcriptome sequencing and network pharmacology-based approach

Full size image

Materials and methods

Peripheral blood samples

Blood samples obtained from PD patients (n = 12) or healthy controls (n = 12) with written informed consent were selected from the Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine from July 2019 to March 2021. All procedures performed in this study involving patients were in accordance with the 1964 Helsinki Declaration and were approved by the Ethics Committee of Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine Hospital (No. KY2022376). Informed consent was obtained from all individual participants prior to any study-related procedures. The inclusion and exclusion criteria were as follows. Inclusion criteria: Inclusion criteria: (1) the diagnosis of PD by a neurologist specialized in movement disorders, according to the clinical criteria proposed by Gelb; (2) stable medication usage; (3) age equal or greater than 60 years. (4) Hoehn and Yahr scale stage 1–3. (5) Mini-Mental State Examination score less than 23 during the initial assessment. Exclusion criteria: (1) a history of any significant neurological disorder; (2) suffered from unstable cardiovascular disease; (3) suffered from other uncontrolled conditions that would interfere with the participant’s safety. Healthy controls were selected from the hospital health examination center and were matched for age (within ± 5 years).

RNA extraction and whole transcriptome RNA sequencing

A total volume of 2ml of blood obtained from all individual participants was extracted using BD PAXgene blood RNA tubes. Then, the blood samples were incubated with PAXgene tubes until the blood cells were completely dissolved. The total RNA was extracted using the TRIzol reagent (Leagene Biotechnology, Beijing, China) following the manufacturer’s protocol. Afterward, isolated RNA was treated with DNAse I and silica-membrane purification (RNeasy kit, Qiagen, Hilden, Germany) and further for Illumina sequencing. An equivalent of 50ng RNA was utilized for the RNA sample preparations. Single reads of a length of 50 base pairs (bp) were sequenced on an Illumina HiSeq2500 according to the manufacturer’s protocol. RNAseq reads were provided in compressed Sanger FASTQ format. Gene expression was calculated on the gene level as raw counts and transcripts per million (TPM).

Identification of differentially expressed genes (DEGs) between PD and healthy controls

Based on the data from whole transcriptome RNA sequencing, gene expression of 24 samples, including 12 blood samples of PD and 12 blood samples of controls were analyzed using Illumina Sequencing Analysis Viewer (Illumina, San Diego, USA). The DEGs were first screened with the restriction of |log2 (Fold-Change)| > 0.5 and p < 0.05 [14,15,16].

Data source of network pharmacology

All ingredients of JCJ were collected from the Traditional Chinese Medicine System Pharmacology (TCMSP) Database [17] (https://tcmspw.com/tcmsp.php). In the TCMSP system, Oral bioavailability (OB) and Drug likeness (DL) is the major parameter to evaluate the quality of active ingredients. As recommended in several studies, the ingredients with OB ≥ 30% and DL ≥ 0.18 are considered to have better pharmacologic effects and can be selected as candidate ingredients for the next step [18]. All the target proteins corresponding to each molecular were also collected from TCMSP and transformed into gene symbols using the UniProt knowledge database (https://www.uniprot.org/).

Protein-protein interaction (PPI) network construction

Firstly, common targets of PD-related DEGs and JCJ were analyzed using the Venn package in R. To further study the interactions between JCJ and PD-related targets, STRING (Search Tool for the Retrieval of Interacting Genes/Proteins https://string-db.org/) was used for predicting protein-protein interactions [19]. The common target proteins with species were set as “Homo sapiens” and the confidence score was set larger than 0.4. Subsequently, the PPI results were exported from STRING and imported into Cytoscape 3.8.0 software [20] to realize visualization and screen out the core targets. The protein ID were obtained from Uniprot database (https://www.uniprot.org/).

Constructing the “Compound-Disease-Target” network

To better demonstrate the mechanism of action of JCJ in PD treatment, we constructed the “Compound-Disease-Target” (C-D-T) network. The networks were built using the Cytoscape 3.8.0 software. In the network plot, nodes represent the PD/JCJ/ingredients/target genes, while edges stand for that they are linked with each other [21, 22]. This “C-D-T” network facilitates scientific interpretation of the complicated relationships among compounds, genes, targets, and diseases.

Functional enrichment analysis

The biological function and pathway of the core targets were analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment. GO enrichment analysis interprets the biological process (BP), cellular component (CC), and molecular function (MF) of target genes in terms of gene function. In our study, we used clusterProfiler package in R to perform the analysis, parameters were set as follows: pvalueCutoff = 0.05, qvalueCutoff = 0.2 [23]. For KEGG pathway analysis, overlapping target genes were executed by the R Project. Only functional terms and pathways with p values < 0.05 were considered statistically significant.

Molecular docking validation

The top 10 target proteins in the PPI network were selected for molecular docking. The 3D structure of the targets was downloaded in the Protein Data Bank (PDB) database (http://www.rcsb.org/). The 2D structure of the drug small molecule was downloaded from the TCMSP Database. The target protein was hydrogenated and converted to * pdbqt format by AutoDock software. Subsequently, the * pdbqt format protein receptor files and ligands were imported to AutoDock tools to construct mating pockets of docking. The docking process was provided with AutoDock tools 1.5.6 with Vina and visualized using the PyMol software (version 2.3.0) [24].

Results

Identification of DEGs between PD and healthy controls based on transcriptome sequencing

Transcriptomic data were obtained from six different cDNA libraries. After removing the adaptor sequence and the low-quality sequence, there were more than 40 million clean reads were obtained from each transcriptome, with Q20 and Q30 were more than 97% and 93%, respectively (Supplemental Table 1). Among clean reads, 96.92–97.83% from each transcriptome were mapped, of which 86.82–97.23% mapped to exons, 1.72–10.14% mapped to introns, and 0.99–3.04% mapped to intergenic regions (Supplemental Tables 2 and 3). Based on the data of whole transcriptome RNA sequencing, the heatmap of DEGs was roughly shown in Fig. 2a, a total number of 2669 DEGs were identified between PD and healthy controls (Fig. 2b and c). Among them, there were 1914 down-regulated genes and 755 up-regulated genes.

Fig. 2
figure 2

Identification of DEGs between PD and controls using transcriptome sequencing. (A) Heatmaps of all DEGs between PD samples and controls. Red and green in heatmaps indicated unigenes with higher and lower expression levels. (B) Venn diagram showing the number of identified genes in PD and healthy controls. (C) Volcano plot of DGEs, Y-axis shows the value of -log10 (FDR), x-axis shows the log2 (fold change) between PD samples and controls. Red and blue spots represented up-regulated and down-regulated DEGs, while grey spots indicate genes with no significant change between two groups

Full size image

Collection of targets of bioactive compounds in JCJ and PD-related targets

To identify the active chemical compounds from JCJ, we applied TCMSP system. In the system, OB ≥ 30% and DL ≥ 0.18 were set as the criteria for screening candidate compounds from each herbal medicine in JCJ. A total number of 38 initial chemical components of JCJ were obtained from TCMSP database (Table 1). Then, the protein targets of these active compounds in JCJ were identified in Uniprot database for normalization, and a total number of 938 targets were obtained, including 81 targets in Rhizoma Cimicifugae, 121 targets in Aurantii Fructus, 69 targets in Angelica sinensis, 438 targets in Achyranthes bidentata, 220 targets in Cistanche deserticola and 9 targets in Alisma orientalis (Supplemental Table 4). After removing duplicate candidates, 260 targets were finally identified.

Table 1 Bioactive compounds of JCJ
Full size table

As shown in Fig. 3a, after mapping JCJ-related targets and PD-related targets in a Venn diagram, 47 overlapping targets were accessed. To further explore the mechanism of these targets, the PPI network was built by inputting 47 overlapping targets into the STRING Database (Fig. 3b). There was a total of 44 nodes and 270 Edges. The nodes with Degree > 20 was regarded as the key node in the network. In the core PPI network in Fig. 3c, the target nodes with the highest degree values were MAPK3, TP53, VEGFA, PPARG, HIF1A, MMP9, FN1, JUN, ERBB2, NFKBIA, MMP2, CCL2, IL10, PTEN. Among them, MAPK3, TP53, VEGFA had the highest degree values. The top-10 JCJ treatment related targets were listed in Table 2.

Fig. 3
figure 3

The potential target for JCJ in the treatment of PD. (A) Venn diagram showing the potential targets for JCJ in the treatment of PD. (B) PPI network of potential PD targets by JCJ. Each node represents relevant targets, and edges stand for protein-protein associations, including known interactions. (C) Core PPI network of core proteins, which contains 14 nodes and 9 edges. Red indicates a higher degree, and yellow represents a lower degree

Full size image
Table 2 Top 10 target of JCJ-related targets for PD treatment
Full size table

The construction of “C-D-T” network

The association between 20 active compounds in JCJ and 47 PD-related target genes was visualized by “C-D-T” network using Cytoscape (Fig. 4). In “C-D-T” network, green square nodes stand for the bioactive compounds from Angelica sinensis, Rhizoma Cimicifugae, Cistanche deserticola, Aurantii Fructus, Achyranthes bidentata in JCJ. The red diamond nodes represent these five herbs in JCJ. Yellow ellipse nodes indicated target genes in PD. Nodes with a greater number of edges have higher degree values, suggesting greater significance in this network. The top bioactive compounds may be the critical nodes in the network and possess an important anti-PD effect, including quercetin, stigmasterol, beta-sitosterol, baicalein, kaempferol, nobiletin, wogonin, naringenin, berberine, palmatine (Table 3).

Fig. 4
figure 4

“Compound-Disease-Target” network of treatment with JCJ for PD. Yellow ellipse nodes indicated target genes in PD, green square nodes stand for the bioactive compounds from JCJ, red diamond nodes represent five herbs in JCJ: Angelica sinensis (DG), Rhizoma Cimicifugae (SM), Cistanche deserticola (RCR), Aurantii Fructus (ZQ), Achyranthes bidentata (NX).

Full size image
Table 3 Top 10 core component from JCJ for PD treatment
Full size table

Enrichment analysis

To further elucidate the underlying mechanism of the key potential anti-PD genes of JCJ, GO enrichment analysis and KEGG pathway enrichment analysis were carried out on 47 intersection targets. The GO analysis consists of BP, CC, and MF. As shown in Fig. 5a, the key targets of JCJ acting on PD were involved in oxidative stress, chemical stress, regulation of angiogenesis, transcription regulator complex, RNA polymerase II transcription regulator complex, RNA polymerase II-specific DNA binding transcription factor binding, DNA binding transcription factor binding, and MAP kinase kinase activity. For KEGG pathways analysis, there were several pathways related to PD were obtained with the condition of P < 0.05, The most significantly enriched signaling pathways were the HIF-1 signaling pathway and the IL-17 signaling pathway (Fig. 5b).

Fig. 5
figure 5

Enrichment analysis of JCJ-PD genes. (A) GO enrichment analysis of key targets of JCJ in treatment of PD, the BP, CC, and MF terms were plotted on the y-axis. (B) KEGG pathway analysis of key targets of JCJ in treatment of PD. Dot plot showing the top 20 enriched KEGG pathways

Full size image

Molecular docking analysis

We selected the top 10 core active components and 10 core targets for molecular docking. The core active components (quercetin, stigmasterol. beta-sitosterol, etc.) were conducted molecular docking with AutoDock Vina. The heatmap of absolute values of the docking score were shown in Fig. 6a. The molecular docking results showed that the binding ability of naringenin, quercetin, baicalein, kaempferol, wogonin to MMP9 was strong (MMP9-naringenin, affinity value=-10.5 kcal/mol; MMP9-quercetin, affinity value=-10.4 kcal/mol; MMP9-baicalein, affinity value=-10 kcal/mol; MMP9- kaempferol, affinity value=-9.9 kcal/mol; MMP9-wogonin, affinity value=-9.3 kcal/mol). In addition, the binding ability of berberine to JUN (JUN-berberine, affinity value=-9.2 kcal/mol), Stigmasterol to MAPK3 and TP53 were also strong (MAPK3-Stigmasterol, affinity value=-9.1 kcal/mol; TP53- Stigmasterol, affinity value=-9.1 kcal/mol). The 3D binding patterns of the target proteins and components were processed and visualized by PyMoL2.3.0 (Fig. 6b). The affinity value of the best binding postures was calculated (Table 4).

Fig. 6
figure 6

Validation of JCJ-PD target by molecular docking analysis. (A) Molecular docking heatmap of PD related targets with main compounds of JCJ. (B) Molecular docking patterns of the top 6 absolute values of the docking score: naringenin (MOL004328) binds to MMP-9 (a), quercetin (MOL000098) to MMP-9 (b), baicalein (MOL002714) to MMP-9 (c), kaempferol (MOL00422) to MMP9 (d), wogonin (MOL000173) to MMP9 (e), berberine (MOL001454) to JUN (f). The hydrogen bonds were indicated by dashed lines

Full size image
Table 4 Affinity value of the protein and compounds
Full size table

Discussion

In our study, with transcriptome sequencing and a network pharmacology-based approach, a total number of 47 genes were identified as JCJ-PD-related targets. Further analysis was conducted within these targets with PPI analysis, C-D-T network analysis, and enrichment analysis. Results demonstrated that MAPK3, TP53, VEGFA, PPARG, HIF1A, MMP9, FN1, JUN, ERBB2, NFKBIA were considered as top 10 targets; quercetin, stigmasterol, beta-sitosterol, baicalein, kaempferol, nobiletin, wogonin, naringenin, berberine, palmatine were most important anti-PD bioactive compounds. Predicted JCJ-PD genes were mostly involved in oxidative stress, and chemical stress processes, and enriched mainly in HIF-1 and IL-17 signaling pathways. In addition, MMP9 was able to stably bound with several bioactive components such as naringenin, quercetin, and baicalein, which was validated by molecular docking. Our main findings not only identified the potential molecular mechanism of JCJ against PD but also paved the way for future therapeutic and mechanistic studies of novel agents for treating PD.

TCM a staple of medical practice for thousands of years within the Chinese community and is now increasingly recognized as an alternative and natural therapy for treating a variety of diseases [25,26,27]. Moreover, many purified chemical drugs used in clinical trials are extracted from herbal plants of TCM, e.g., artemisinin, a natural product of anti-malarial drug, was extracted from Artemisia annua L. by Youyou Tu’s team [28]. Nowadays, TCM has made remarkable achievements in the research and treatment of PD because of its advantages of multi-component, multi-target, and multi-stage treatment effects [29,30,31]. However, inferring the mechanisms of TCM, finding a novel candidate for treating PD remains challenging.

Transcriptome sequencing is a commonly used technique for identifying differential expression in case–control or cohort studies [32]. In our study, we enrolled 12 PD patients and 12 matched controls. On average, we obtained 6.86 GB clean data in each sample, and around 46 million clean reads were assembled after filtered and trimmed the raw data. With further analysis, 2669 DEGs between PD and control were identified, in which 1914 were down-regulated genes and 755 were up-regulated genes. Whether there is a regulatory association between JCJ and these genes needs to be further clarified.

JCJ is a classical herbal formula that has been administered for PD in clinical practice in China [9, 10]. JCJ consists of six herbal drugs, i.e., Angelica sinensis, Achyranthes bidentata, Aurantii Fructus, Rhizoma Cimicifugae, Cistanche deserticola and Alisma orientalis. As predicted by network pharmacological methods, a total number of 38 initial chemical components of JCJ and 260 targets were finally identified. Finally, were overlapping with the results of transcriptome sequencing, and considered as JCJ-PD-related genes.

Of these 47 genes, MAPK3, TP53, and VEGFA were recognized as the most crucial genes that participated in the JCJ treatment of PD. MAPK3 (also known as ERK1), an key member of Mitogen-activated protein kinase (MAPK) signaling pathway, its phosphorylation can be activated by a MAPK kinase (MAPKK) [33]. Previous studies have demonstrated that MAPK3 is required for mammalian normal neural crest development [34]. In PD rat model, stimulation of MAPK signaling is involved in mediating the neuroprotective effects of Nootkatone [35]. Others have found that inhibition of MAPK3 conferred protection against mutant LRRK2-induced neurite shortening in PD-induced cognitive dysfunction [36]. TP53 is commonly known as a tumor suppressor gene which more likely to mutate in the cancer development [37]. Moreover, it also involved in regulation of dopaminergic neuronal cell death or neuronal terminal damage [38]. A single-cell genomic profiling of human dopamine neurons showed that upregulation of the transcription factor encoded by TP53 provides a link to PD, in which TP53 has been implicated in motor neuron death [39]. Prior research has indicated that TP53-induced glycolysis and apoptosis regulator (TIGAR) plays a significant role in the oxidative stress-induced damage of dopamine neurons in PD induced by the MPTP [40]. Furthermore, studies have shown that vascular endothelial growth factor A (VEGFA) is predominantly expressed in astrocytes and contributes to the disruption of the blood-brain barrier in PD, as previously reported [41, 42].

Based on the GO and KEGG pathway analyzed results, JCJ may treat PD through biological processes such as response to oxidative stress, response chemical stress. In addition, most of its targets were enriched in transcription regulatory complexes and DNA binding transcription factor. As for signaling pathways, Hypoxia inducible factor-1 (HIF-1) signaling pathway, exhibiting the highest gene count enrichment among the PD-related signal pathways. HIF-1 is an oxygen tension dependent transcription factor, which is responsible for cell adaptation and survival under hypoxia [43]. HIF-1 regulates the expression of many target genes and participates in many cellular processes, e.g., substance synthesis, glucose energy metabolism, cell proliferation and cell phase regulation [44, 45]. Many evidences show that HIF-1 is related to the etiology, disease progression, treatment and other processes of PD [46].

This study showed that the core components of JCJ to improve PD were quercetin, stigmasterol, beta-sitosterol, baicalein, kaempferol, nobiletin, wogonin, naringenin, berberine, and palmatine. Combined with the results of molecular docking, it is revealed that naringenin, quercetin, baicalein, kaempferol and wogonin have the best binding performance with cytokines and matrix metalloproteinases-9 (MMP-9). MMP9 is a type IV collagenase and a member of the endopeptidase family of proteins, which highly expressed in the brain and recognized as a unique player in brain physiology and pathology [47, 48]. Previous studies have shown that naringenin could attenuated diabetic neuropathic pain by modulating the expression of MMP-9 [49], and may have protective effect on ischemic stroke by down-regulating the expression of NOD2, RIP2, NF-κB, MMP-9 [50]. In recent years, several studies have focused on quercetin’s effect on MMP-9, e.g., quercetin could inhibit the expression of MMP-9 via the AKT and ERK signalling pathways in gliomas [51]. In addition, Zhao et al.’s study demonstrated that quercetin improved the blood-brain barrier dysfunction by increasing the expression of ZO-1, Claudin-5, β-catenin, and LEF1, and decreasing the expression of MMP-9, GSK-3β and Axin in cerebral ischemia reperfusion model [52]. Baicalein also showed a protective effect on hippocampal neuronal damage by inhibiting MMP-9 activity [53]. At present, little is known regarding the effect of kaempferol and wogonin on MMP-9 in neurological diseases model. Our study might provide the new views for bioactive compounds of TCM in treating PD.

However, the present study has several limitations: (1) In this study, we employed transcriptome sequencing using peripheral blood samples obtained from patients diagnosed with PD. While the results obtained from this analysis may hold potential for the diagnosis of PD, it is important to note that diagnostic-related investigations have not yet been performed. (2) There is lack of pharmacodynamic and molecular biologic experiments. Additional animal studies or even clinical trials are desperately required to further verify our research results.

Conclusion

To sum up, based on transcriptome sequencing, network pharmacology and molecular docking, this study preliminarily explored the potential mechanism of JCJ in the treatment of PD, which provides a new research direction for further exploring the mechanism of JCJ in the treatment of PD, and also provides a theoretical basis for the clinical application of JCJ in the treatment of PD. However, further pharmacological and animal experiments need to be carried out in the later stage to confirm the main regulatory target of JCJ for PD.

Data Availability

The raw sequence data reported in this paper have been deposited in the Genome Sequence Archive (Genomics, Proteomics & Bioinformatics 2021) in national Genomics data Center (Nucleic Acids Res 2022), China National Center for Bioinformation / Beijing Institute of Genomics, Chinese Academy of Science (GSA-Human: HRA004091) that are publicly accessible at https://ngdc.cncb.ac.cn/gsa-human/.

Abbreviations

BP:

Biological process

CC:

Cellular component

C-D-T:

Compound-Disease-Target

DEGs:

Differentially expressed genes

DL:

Drug likeness

GO:

Gene Ontology

HIF-1α:

Hypoxia inducible factor-α

JCJ:

Ji Chuan Jian

KEGG:

Kyoto Encyclopedia of Genes and Genomes

MAPK:

Mitogen-activated protein kinase

MF:

Molecular function

MMP9:

Matrix metalloproteinases-9

OB:

Oral bioavailability

PD:

Parkinson’s disease

PPI:

Protein-protein interaction

TCM:

Traditional Chinese Medicine

TCMSP:

Traditional Chinese Medicine System Pharmacology

References

  1. Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, et al. Prevalence of Parkinson’s disease across North America. NPJ Parkinson’s disease. 2018;4:21. https://doi.org/10.1038/s41531-018-0058-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Samii A, Nutt JG, Ransom BR. Parkinson’s disease. Lancet (London England). 2004;363 9423:1783–93. https://doi.org/10.1016/s0140-6736(04)16305-8.

    Article  Google Scholar 

  3. Pfeiffer RF. Non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2016;22(Suppl 1):119–22. https://doi.org/10.1016/j.parkreldis.2015.09.004.

    Article  Google Scholar 

  4. Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P. Apathy in Parkinson’s disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol. 2015;14 5:518–31. https://doi.org/10.1016/s1474-4422(15)00019-8.

    Article  Google Scholar 

  5. Walker L, Stefanis L, Attems J. Clinical and neuropathological differences between Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies - current issues and future directions. J Neurochem. 2019;150 5:467–74. https://doi.org/10.1111/jnc.14698.

    Article  CAS  Google Scholar 

  6. Li G, Ma J, Cui S, He Y, Xiao Q, Liu J, et al. Parkinson’s disease in China: a forty-year growing track of bedside work. Translational neurodegeneration. 2019;8:22. https://doi.org/10.1186/s40035-019-0162-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson Disease: a review. JAMA. 2020;323 6:548–60. https://doi.org/10.1001/jama.2019.22360.

    Article  Google Scholar 

  8. Vijiaratnam N, Simuni T, Bandmann O, Morris HR, Foltynie T. Progress towards therapies for disease modification in Parkinson’s disease. Lancet Neurol. 2021;20 7:559–72. https://doi.org/10.1016/s1474-4422(21)00061-2.

    Article  CAS  Google Scholar 

  9. Da-chao C. Clinical curative effect of Jiawei Jichuan Decoction in treatment of constipation of patients with Parkinson’s Disease. Syst Med. 2019;4 04:1–2. https://doi.org/10.19368/j.cnki.2096-1782.2019.04.001.

    Article  Google Scholar 

  10. Wei PENG, Yingjun OUYANG, Jianmin YU, Jingzhou CAI, Dan X. Clinical effect of jichuanjian decoction and acupoint application on the treatment of constipation in Parkinson’s disease. Guangzhou Med J. 2020;51 03:53–6.

    Google Scholar 

  11. Peng S, Wang C, Ma J, Jiang K, Jiang Y, Gu X, et al. Achyranthes bidentata polypeptide protects dopaminergic neurons from apoptosis in Parkinson’s disease models both in vitro and in vivo. Br J Pharmacol. 2018;175 4:631–43. https://doi.org/10.1111/bph.14110.

    Article  CAS  Google Scholar 

  12. Gao MR, Wang M, Jia YY, Tian DD, Liu A, Wang WJ, et al. Echinacoside protects dopaminergic neurons by inhibiting NLRP3/Caspase-1/IL-1β signaling pathway in MPTP-induced Parkinson’s disease model. Brain Res Bull. 2020;164:55–64. https://doi.org/10.1016/j.brainresbull.2020.08.015.

    Article  CAS  PubMed  Google Scholar 

  13. Yang X, Yv Q, Ye F, Chen S, He Z, Li W, et al. Echinacoside protects dopaminergic neurons through regulating IL-6/JAK2/STAT3 pathway in Parkinson’s Disease Model. Front Pharmacol. 2022;13:848813. https://doi.org/10.3389/fphar.2022.848813.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Huang Y, Yang DD, Li XY, Fang DL, Zhou WJ. ZBP1 is a significant pyroptosis regulator for systemic lupus erythematosus. Annals of translational medicine. 2021;9 24:1773. https://doi.org/10.21037/atm-21-6193.

    Article  CAS  Google Scholar 

  15. Bian Z, Fan R, Xie L. A Novel cuproptosis-related prognostic gene signature and validation of Differential expression in Clear Cell Renal Cell Carcinoma. Genes. 2022;13:5. https://doi.org/10.3390/genes13050851.

    Article  CAS  Google Scholar 

  16. You J, Li H, Wei Y, Fan P, Zhao Y, Yi C, et al. Novel pyroptosis-related gene signatures identified as the prognostic biomarkers for bladder carcinoma. Front Oncol. 2022;12:881860. https://doi.org/10.3389/fonc.2022.881860.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Ru J, Li P, Wang J, Zhou W, Li B, Huang C, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;6:13. https://doi.org/10.1186/1758-2946-6-13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Fan JH, Xu MM, Zhou LM, Gui ZW, Huang L, Li XG, et al. Integrating network pharmacology deciphers the action mechanism of Zuojin capsule in suppressing colorectal cancer. Phytomedicine: Int J phytotherapy phytopharmacology. 2022;96:153881. https://doi.org/10.1016/j.phymed.2021.153881.

    Article  CAS  Google Scholar 

  19. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47 D1:D607–d13. https://doi.org/10.1093/nar/gky1131.

    Article  CAS  Google Scholar 

  20. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13 11:2498–504. https://doi.org/10.1101/gr.1239303.

    Article  CAS  Google Scholar 

  21. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, et al. Integration of biological networks and gene expression data using Cytoscape. Nat Protoc. 2007;2 10:2366–82. https://doi.org/10.1038/nprot.2007.324.

    Article  CAS  Google Scholar 

  22. Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinf (Oxford England). 2005;21 16:3448–9. https://doi.org/10.1093/bioinformatics/bti551.

    Article  CAS  Google Scholar 

  23. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16 5:284–7. https://doi.org/10.1089/omi.2011.0118.

    Article  CAS  Google Scholar 

  24. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–61. https://doi.org/10.1002/jcc.21334.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Hao P, Jiang F, Cheng J, Ma L, Zhang Y, Zhao Y. Traditional Chinese Medicine for Cardiovascular Disease: evidence and potential mechanisms. J Am Coll Cardiol. 2017;69 24:2952–66. https://doi.org/10.1016/j.jacc.2017.04.041.

    Article  Google Scholar 

  26. Huang K, Zhang P, Zhang Z, Youn JY, Wang C, Zhang H, et al. Traditional chinese medicine (TCM) in the treatment of COVID-19 and other viral infections: efficacies and mechanisms. Pharmacol Ther. 2021;225:107843. https://doi.org/10.1016/j.pharmthera.2021.107843.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Guo H, Liu MP. Mechanism of traditional chinese medicine in the treatment of allergic rhinitis. Chin Med J. 2013;126 4:756–60.

    Google Scholar 

  28. Kong LY, Tan RX. Artemisinin, a miracle of traditional chinese medicine. Nat Prod Rep. 2015;32 12:1617–21. https://doi.org/10.1039/c5np00133a.

    Article  CAS  Google Scholar 

  29. Feng ST, Wang XL, Wang YT, Yuan YH, Li ZP, Chen NH, et al. Efficacy of traditional chinese medicine combined with selective serotonin reuptake inhibitors on the treatment for Parkinson’s Disease with Depression: a systematic review and Meta-analysis. Am J Chin Med. 2021;49 3:627–43. https://doi.org/10.1142/s0192415x21500282.

    Article  CAS  Google Scholar 

  30. Wang L, Yang YF, Chen L, He ZQ, Bi DY, Zhang L, et al. Compound Dihuang Granule inhibits Nigrostriatal Pathway apoptosis in Parkinson’s Disease by suppressing the JNK/AP-1 pathway. Front Pharmacol. 2021;12:621359. https://doi.org/10.3389/fphar.2021.621359.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Wang ZY, Liu J, Zhu Z, Su CF, Sreenivasmurthy SG, Iyaswamy A, et al. Traditional chinese medicine compounds regulate autophagy for treating neurodegenerative disease: a mechanism review. Biomed pharmacotherapy = Biomedecine pharmacotherapie. 2021;133:110968. https://doi.org/10.1016/j.biopha.2020.110968.

    Article  CAS  PubMed  Google Scholar 

  32. Zhao Y, Qin L, Pan H, Liu Z, Jiang L, He Y, et al. The role of genetics in Parkinson’s disease: a large cohort study in chinese mainland population. Brain. 2020;143 7:2220–34. https://doi.org/10.1093/brain/awaa167.

    Article  Google Scholar 

  33. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103 2:239 – 52; doi: 10.1016/s0092-8674(00)00116-1.

  34. Newbern J, Zhong J, Wickramasinghe RS, Li X, Wu Y, Samuels I, et al. Mouse and human phenotypes indicate a critical conserved role for ERK2 signaling in neural crest development. Proc Natl Acad Sci USA. 2008;105 44:17115–20. https://doi.org/10.1073/pnas.0805239105.

    Article  Google Scholar 

  35. Yao Z, Li J, Bian L, Li Q, Wang X, Yang X, et al. Nootkatone alleviates rotenone-induced Parkinson’s disease symptoms through activation of the PI3K/Akt signaling pathway. Phytother Res. 2022. https://doi.org/10.1002/ptr.7552.

    Article  PubMed  Google Scholar 

  36. Verma M, Callio J, Otero PA, Sekler I, Wills ZP, Chu CT. Mitochondrial calcium Dysregulation contributes to Dendrite Degeneration mediated by PD/LBD-Associated LRRK2 mutants. J neuroscience: official J Soc Neurosci. 2017;37 46:11151–65. https://doi.org/10.1523/jneurosci.3791-16.2017.

    Article  CAS  Google Scholar 

  37. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2(1):a001008. https://doi.org/10.1101/cshperspect.a001008.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Lu T, Kim P, Luo Y. Tp53 gene mediates distinct dopaminergic neuronal damage in different dopaminergic neurotoxicant models. Neural regeneration research. 2017;12 9:1413–7. https://doi.org/10.4103/1673-5374.215243.

    Article  CAS  Google Scholar 

  39. Kamath T, Abdulraouf A, Burris SJ, Langlieb J, Gazestani V, Nadaf NM, et al. Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson’s disease. Nat Neurosci. 2022;25 5:588–95. https://doi.org/10.1038/s41593-022-01061-1.

    Article  CAS  Google Scholar 

  40. Ge J, Lin H, Yang J, Li Q, Zhou J, Qin Z, et al. TP53-induced glycolysis and apoptosis regulator (TIGAR) ameliorates lysosomal damage in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-mediated mouse model of Parkinson’s disease. Toxicol Lett. 2021;339:60–9. https://doi.org/10.1016/j.toxlet.2020.12.011.

    Article  CAS  PubMed  Google Scholar 

  41. Lan G, Wang P, Chan RB, Liu Z, Yu Z, Liu X, et al. Astrocytic VEGFA: an essential mediator in blood-brain-barrier disruption in Parkinson’s disease. Glia. 2022;70(2):337–53. https://doi.org/10.1002/glia.24109.

    Article  CAS  PubMed  Google Scholar 

  42. Wood H. VEGFA mediates blood-brain barrier disruption in Parkinson disease. Nat reviews Neurol. 2022;18(1:1). https://doi.org/10.1038/s41582-021-00594-6.

  43. Schumacker PT. Hypoxia-inducible factor-1 (HIF-1). Crit Care Med. 2005;33. https://doi.org/10.1097/01.ccm.0000191716.38566.e0. 12 Suppl:S423-5.

  44. Yee Koh M, Spivak-Kroizman TR, Powis G. HIF-1 regulation: not so easy come, easy go. Trends Biochem Sci. 2008;33 11:526–34. https://doi.org/10.1016/j.tibs.2008.08.002.

    Article  CAS  Google Scholar 

  45. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995;92 12:5510–4. https://doi.org/10.1073/pnas.92.12.5510.

    Article  Google Scholar 

  46. Lestón Pinilla L, Ugun-Klusek A, Rutella S, De Girolamo LA. Hypoxia Signaling in Parkinson’s Disease: there is use in asking “What HIF? Biology. 2021;10:8. https://doi.org/10.3390/biology10080723.

    Article  CAS  Google Scholar 

  47. Vafadari B, Salamian A, Kaczmarek L. MMP-9 in translation: from molecule to brain physiology, pathology, and therapy. J Neurochem. 2016;139(Suppl 2):91–114. https://doi.org/10.1111/jnc.13415.

    Article  CAS  PubMed  Google Scholar 

  48. Navaratna D, Fan X, Leung W, Lok J, Guo S, Xing C, et al. Cerebrovascular degradation of TRKB by MMP9 in the diabetic brain. J Clin Investig. 2013;123 8:3373–7. https://doi.org/10.1172/jci65767.

    Article  Google Scholar 

  49. Singh P, Bansal S, Kuhad A, Kumar A, Chopra K. Naringenin ameliorates diabetic neuropathic pain by modulation of oxidative-nitrosative stress, cytokines and MMP-9 levels. Food Funct. 2020;11 5:4548–60. https://doi.org/10.1039/c9fo00881k.

    Article  CAS  Google Scholar 

  50. Bai X, Zhang X, Chen L, Zhang J, Zhang L, Zhao X, et al. Protective effect of naringenin in experimental ischemic stroke: down-regulated NOD2, RIP2, NF-κB, MMP-9 and up-regulated claudin-5 expression. Neurochem Res. 2014;39 8:1405–15. https://doi.org/10.1007/s11064-014-1326-y.

    Article  CAS  Google Scholar 

  51. Pan HC, Jiang Q, Yu Y, Mei JP, Cui YK, Zhao WJ. Quercetin promotes cell apoptosis and inhibits the expression of MMP-9 and fibronectin via the AKT and ERK signalling pathways in human glioma cells. Neurochem Int. 2015;80:60–71. https://doi.org/10.1016/j.neuint.2014.12.001.

    Article  CAS  PubMed  Google Scholar 

  52. Jin Z, Ke J, Guo P, Wang Y, Wu H. Quercetin improves blood-brain barrier dysfunction in rats with cerebral ischemia reperfusion via wnt signaling pathway. Am J translational Res. 2019;11 8:4683–95.

    Google Scholar 

  53. Lee JH, Lee SR. The effect of Baicalein on hippocampal neuronal damage and metalloproteinase activity following transient global cerebral ischaemia. Phytother Res. 2012;26 11:1614–9. https://doi.org/10.1002/ptr.4644.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This work was supported by the Natural Science Foundation of Jiangsu Province (Grant No. BK20220469) and the Natural Science Research of Jiangsu Higher Education Institutions of China (Grant No. 22KJB360003).

Author information

Author notes

  1. Yao Wu and Yu Bai contributed equally to this work.

Authors and Affiliations

  1. Department of Neurology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China

    Yao Wu

  2. School of Chinese Medicine, School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China

    Yu Bai, Sirui Huang & Yue Hu

  3. Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China

    Yan Lu, Zhennian Zhang, Yang Zhao, Lili Tang, Yan Liang & Chengcheng Xu

Authors
  1. Yao Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yan Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhennian Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yang Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sirui Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lili Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yan Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yue Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Chengcheng Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YW and BY obtained the data, performed the analysis, and wrote the initial manuscript. YL, ZZ, and YZ provided the statistical method. LT, YL, and SH did the molecular docking part. YH and CX designed and supervised the study, and revised the manuscript. All authors contributed to the article and approved the submitted version. YW and BY contributed equally to this work.

Corresponding authors

Correspondence to Yue Hu or Chengcheng Xu.

Ethics declarations

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate

This study was performed in line with the principles of the Declaration of Helsinki (1964) and and the relevant guidelines and regulations. Approval was granted by the Ethics Committee of Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine (No. KY2022376). Written informed consent was obtained from all participants before any research-relevant procedure started, and all were informed that they could withdraw from the study for no reason.

Consent for publication

Not applicable.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Additional file 1

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, Y., Bai, Y., Lu, Y. et al. Transcriptome sequencing and network pharmacology-based approach to reveal the effect and mechanism of Ji Chuan Jian against Parkinson’s disease. BMC Complement Med Ther 23, 182 (2023). https://doi.org/10.1186/s12906-023-03999-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12906-023-03999-6

Keywords

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us